Loncastuximab Tesirine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NICE (England) and SMC (Scotland) recommended or restricted loncastuximab tesirine, while AOTMIT (Poland), CIPM (Spain) and PBAC (Australia), among others, did not recommend it.
The record spans 3.8 years, opening at AWMSG (Wales) on 30 Oct 2022 and running to 2026.
No assessment is on file from HAS (France), PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 7 of 8 records date from 2023 or later.
Against its own class, loncastuximab tesirine is an outlier: 33% of its decisive outcomes were positive, where molecules sharing ATC class L01F average 73%.
4 distinct indication wordings are recorded for loncastuximab tesirine by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 8 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess loncastuximab tesirine, on 30 Oct 2022; PBAC (Australia) did not open a file until 2026 — a wide spread of 3.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 8 dated records fall in 2024 alone.
8 of the 18 agencies in this archive hold a record for loncastuximab tesirine.
The full ledger for loncastuximab tesirine reads 4 not recommended, 1 no benefit, 1 restricted and 1 recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 26 Sep 2024 | Indicaciones terapéuticas autorizadas: Zynlonta está indicado como monoterapia para el tratamiento de pacientes adultos … | not financed by the SNS · art. 92 c, e | source |
| AOTMIT (Poland) | 2 Jul 2024 | programu lekowego „Leczenie chorych na chłoniaki B-komórkowe (ICD-10: C82, C83, C85) | not recommended | source |
| ZIN (Netherlands) | 12 Jun 2024 | Advies - niet vergoeden loncastuximab tesirine (Zynlonta®) voor de behandeling van lymfeklierkanker | not reimbursed | source |
| AIFA (Italy) | 16 Mar 2024 | ZYNLONTA in monoterapia è indicato per il trattamento di pazienti adulti con linfoma diffuso a grandi | innovative status not granted · reimbursed class H | source |
| SMC (Scotland) | 12 Feb 2024 | As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or m… | accepted (restricted) | source |
3 further decisions for loncastuximab tesirine, across 3 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 3 further source documents.
Related molecules
- axicabtagene ciloleucel — divergent outcome (not recommended vs recommended) on a shared indication
- tisagenlecleucel — divergent outcome (not recommended vs recommended) on a shared indication
- glofitamab — divergent outcome (not recommended vs recommended) on a shared indication
- epcoritamab — divergent outcome (not recommended vs recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
Coverage: 8 decisions for loncastuximab tesirine from 8 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.